Robert Bielik

Robert Bielik

Auto-generated profile, based on publicly available information

Robert Bielik

Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
RHRichard L. Hesketh
Richard L. Hesketh
JWJiazheng Wang
Jiazheng Wang
AWAlan J. Wright
Alan J. Wright
DLDavid Y. Lewis
David Y. Lewis
ADAlice E. Denton
Alice E. Denton
KBKevin Brindle
Kevin Brindle
Metabolic imaging has been widely used to measure the early responses of tumors to treatment. Here, we assess the abilities of PET measurement of [18F]FDG uptake and MRI measurement of hyperpolarized [1-13C]pyruvate metabolism to detect early changes in glycolysis following treatment-induced cell death in human colorectal (Colo205) and breast adenocarcinoma (MDA-MB-231) xenografts in mice. A TRAIL agonist that binds to human but not mouse cells induced tumor-selective cell death. Tumor glycolysis was assessed by injecting [1,6-13C2]glucose and measuring 13C-labeled metabolites in tumor extracts. Injection of hyperpolarized [1-13C]pyruvate induced rapid reduction in lactate labeling. This decrease, which correlated with an increase in histologic markers of cell death and preceded decrease in tumor volume, reflected reduced flux from glucose to lactate and decreased lactate concentration. However, [18F]FDG uptake and phosphorylation were maintained following treatment, which has been attributed previously to increased [18F]FDG uptake by infiltrating immune cells. Quantification of [18F]FDG uptake in flow-sorted tumor and immune cells from disaggregated tumors identified CD11b+/CD45+ macrophages as the most [18F]FDG-avid cell type present, yet they represented <5% of the cells present in the tumors and could not explain the failure of [18F]FDG-PET to detect treatment response. MRI measurement of hyperpolarized [1-13C]pyruvate metabolism is therefore a more sensitive marker of the early decreases in glycolytic flux that occur following cell death than PET measurements of [18F]FDG uptake. Significance: These findings demonstrate superior sensitivity of MRI measurement of hyperpolarized [1-13C]pyruvate metabolism versus PET measurement of 18F-FDG uptake for detecting early changes in glycolysis following treatment-induced tumor cell death.

17 March 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Gaurav MalviyaGaurav Malviya
Gaurav Malviya
TLTamsin R.M. Lannagan
Tamsin R.M. Lannagan
EJEmma Johnson
Emma Johnson
AMAgata Mackintosh
Agata Mackintosh
RBRobert Bielik
Robert Bielik
DLDavid Y. Lewis
David Y. Lewis
Purpose: The current approach for molecular subtyping of colon cancer relies on gene expression profiling, which is invasive and has limited ability to reveal dynamics and spatial heterogeneity. Molecular imaging techniques, such as PET, present a noninvasive alternative for visualizing biological information from tumors. However, the factors influencing PET imaging phenotype, the suitable PET radiotracers for differentiating tumor subtypes, and the relationship between PET phenotypes and tumor genotype or gene expression–based subtyping remain unknown. Experimental Design: In this study, we conducted 126 PET scans using four different metabolic PET tracers, [18F]fluorodeoxy-D-glucose ([18F]FDG), O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET), 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT), and [11C]acetate ([11C]ACE), using a spectrum of five preclinical colon cancer models with varying genetics (BMT, AKPN, AK, AKPT, KPN), at three sites (subcutaneous, orthograft, autochthonous) and at two tumor stages (primary vs. metastatic). Results: The results demonstrate that imaging signatures are influenced by genotype, tumor environment, and stage. PET imaging signatures exhibited significant heterogeneity, with each cancer model displaying distinct radiotracer profiles. Oncogenic Kras and Apc loss showed the most distinctive imaging features, with [18F]FLT and [18F]FET being particularly effective, respectively. The tissue environment notably impacted [18F]FDG uptake, and in a metastatic model, [18F]FET demonstrated higher uptake. Conclusions: By examining factors contributing to PET-imaging phenotype, this study establishes the feasibility of noninvasive molecular stratification using multiplex radiotracer PET. It lays the foundation for further exploration of PET-based subtyping in human cancer, thereby facilitating noninvasive molecular diagnosis.

12 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HWHannah L Williams
Hannah L Williams
NPNicolas Poulain
Nicolas Poulain
IPIan Powley
Ian Powley
SMSilvia Martinelli
Silvia Martinelli
RBRobert Bielik
Robert Bielik
JQJohn Le Quesne
John Le Quesne
Adenocarcinoma of the lung (LUAD) is a common and highly lethal disease. Clinical grading of disease strongly predicts recurrence and survival after surgery and is determined by morphological assessment of histological growth patterns in resected tumours. The molecular basis of growth pattern is poorly understood at present, as are the mechanisms linking growth pattern to recurrence and death. Interestingly, the two archetypal lethal morphologies, solid and micropapillary patterns, are characterised by their biphasic appearance. Both have an epithelial fraction which is in direct stromal contact, and a fraction which is not. This morphological variance seems likely to represent plasticity, and to be causally linked to mechanisms of virulence. To investigate the gene expression changes related to growth pattern both intra- and intertumoral, we applied spatial transcriptomics (Nanostring GeoMx DSP) to tissue microarray specimens of primary resected human lung adenocarcinoma. Using a variety of region-of-interest (ROI) selection strategies, we sampled 160 pure epithelial ROIs across 7 distinct morphological features of LUAD from 51 patients. Analyses of gene expression reveal fundamental trajectories connecting growth patterns, and crucial modes of plasticity which underly high-risk morphologies. These modes suggest mechanisms for the origins of growth pattern and mechanisms of virulence. Our work highlights dramatic divergence in gene expression programmes between highly lethal but morphologically diverse modes of tumour growth. Furthermore, it provides an explanation for how microscopically localised hypoxia in the primary tumour helps to establish and maintain survival strategies which ultimately determine morphology-specific mechanisms of tumour metastasis, suggesting new therapeutic vulnerabilities.

31 March 2023
Verified
Other
Open access
RHRichard L. Hesketh
Richard L. Hesketh
JWJiazheng Wang
Jiazheng Wang
AWAlan J. Wright
Alan J. Wright
DLDavid Y. Lewis
David Y. Lewis
ADAlice E. Denton
Alice E. Denton
KBKevin M. Brindle
Kevin M. Brindle
Figure S1. Timeline of injections and imaging for the main treatment-response study. Figure S2. Tumor volume measurements for (a) Colo205 and (b) MDA-MB-231 tumors (b & e) before and (c & f) 24 h after MEDI3039 treatment. Figure S3. Confirmation that [18F]FDG uptake was similar before and 24 h after treatment. Examples of autoradiography of whole-body axial sections of Colo205 tumor-bearing mice (the tumors are outlined) before (a - c) and 24 h after treatment (d - f). Figure S4. Dynamic contrast enhanced MRI measurements of perfusion in Colo205 tumors before and 24 h after treatment with MEDI3039. Figure S5. RadioHPLC measurements of [18F]FDG metabolism in Colo205 tumors 24 h after control (drug vehicle) or MEDI3039 treatment. Table S1. Colo205 mice that underwent fluorescence, bioluminescence, hyperpolarized MR and PET-CT imaging and reasons for their exclusion. Table S2. MDA-MB-231 mice that underwent fluorescence, bioluminescence, hyperpolarized MR and PET-CT imaging and reasons for their exclusion. Table S3. Antibodies used for Western blotting. Table S4. Expression of the transporters and enzymes and the activities of the enzymes involved in [18F]FDG and [1-13C]pyruvate uptake and metabolism in Colo205 tumors.

31 March 2023
Verified
Other
Open access
RHRichard L. Hesketh
Richard L. Hesketh
JWJiazheng Wang
Jiazheng Wang
AWAlan J. Wright
Alan J. Wright
DLDavid Y. Lewis
David Y. Lewis
ADAlice E. Denton
Alice E. Denton
KBKevin M. Brindle
Kevin M. Brindle
Figure S1. Timeline of injections and imaging for the main treatment-response study. Figure S2. Tumor volume measurements for (a) Colo205 and (b) MDA-MB-231 tumors (b & e) before and (c & f) 24 h after MEDI3039 treatment. Figure S3. Confirmation that [18F]FDG uptake was similar before and 24 h after treatment. Examples of autoradiography of whole-body axial sections of Colo205 tumor-bearing mice (the tumors are outlined) before (a - c) and 24 h after treatment (d - f). Figure S4. Dynamic contrast enhanced MRI measurements of perfusion in Colo205 tumors before and 24 h after treatment with MEDI3039. Figure S5. RadioHPLC measurements of [18F]FDG metabolism in Colo205 tumors 24 h after control (drug vehicle) or MEDI3039 treatment. Table S1. Colo205 mice that underwent fluorescence, bioluminescence, hyperpolarized MR and PET-CT imaging and reasons for their exclusion. Table S2. MDA-MB-231 mice that underwent fluorescence, bioluminescence, hyperpolarized MR and PET-CT imaging and reasons for their exclusion. Table S3. Antibodies used for Western blotting. Table S4. Expression of the transporters and enzymes and the activities of the enzymes involved in [18F]FDG and [1-13C]pyruvate uptake and metabolism in Colo205 tumors.

15 April 2024
Verified
Other
Open access
Gaurav MalviyaGaurav Malviya
Gaurav Malviya
TLTamsin R.M. Lannagan
Tamsin R.M. Lannagan
EJEmma Johnson
Emma Johnson
AMAgata Mackintosh
Agata Mackintosh
RBRobert Bielik
Robert Bielik
DLDavid Y. Lewis
David Y. Lewis
Colon cancer models have genotypic and phenotypic diversity. A, The alleles in the GEMM used in this study. Cre, Cre recombinase; ER, estrogen receptor; loxP, Cre-loxP recombination site. B, Oncoprint showing the prevalence of genetic alterations of the alleles in A, determined using cBioportal from the Colorectal Adenocarcinoma, TCGA, PanCancer Atlas (n = 524). C, Venn diagrams of the genetic crossing strategies for the GEMM. D, Heatmap illustrating correlation of intestinal cancer GEMM gene expression with patient-derived CMS profiles. E, Gene set enrichment analysis for the GEMM with the Molecular Signatures Database (MSigDB) hallmark gene set. Data were ordered using hierarchal clustering. Extended heatmap is shown in Supplementary Fig. S1. (A, Created with BioRender.com.)